Objective-The proatherogenic effect of IL-18 is shown to be dependent on IFN-␥ production. It is believed that activated T cells play a proatherogenic role through secretion of IFN-␥. However, recent studies in vitro have shown that macrophages, NK cells, and even vascular smooth muscle cells may also secrete IFN-␥ after stimulation by cytokines like IL-18. We therefore investigated whether cells other than activated T cells can play a proatherogenic role via IFN-␥ secretion under the stimulation of IL-18 in vivo. Methods and Results-SCID/apoE knockout mice were injected intraperitoneally with either IL-18 or phosphate-buffered saline 3 times per week for 7 weeks. Our results show that administration of IL-18 leads to 3-fold larger lesions and 2-fold higher circulating IFN-␥ despite the absence of T cells. In addition, increased IFN-␥, accompanied by elevation of the scavenger receptor/chemokine CXCL16, was observed in both lesions and spleens. 
A therosclerosis is a disease of the large and medium arteries, characterized by lipid-laden inflammatory lesions in the vessel wall. [1] [2] [3] It has been found that atherosclerotic lesions of all stages contain significant amounts of macrophages and activated T cells that express cytokines. 1, 4, 5 Interferon (IFN)-␥ has been proposed to be a key cytokine in atherogenesis. 2, 4, 5 IFN-␥ activates macrophages, which in turn produce proinflammatory cytokines, oxygen radicals, and metalloproteinases. IFN-␥ also stimulates endothelial cells to express adhesion molecules and reduces contractility and fibrogenesis in vascular smooth muscle cells (SMCs), as well as inhibits the ATP-binding cassette protein-1, which mediates cholesterol efflux from macrophages. 6 CXCL16, a chemokine of the CXC family that has been found in the atherosclerotic lesion with the function of a scavenger receptor, can also be induced by IFN-␥. 7, 8 Studies have shown that gene deficiency in either IFN-␥ receptor 9 or IFN-␥ itself 10, 11 results in reduced lesion size, whereas direct injection of IFN-␥ in apolipoprotein E knockout (apoE KO) mice accelerates lesion development. 12 
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IFN-␥ was originally considered to be restricted to T cells and NK cells. 13 
Mice and Experimental Design
Female SCID/apoE KO mice on the C57BL/6 background were obtained from our own breeding and housed in a specific pathogenfree facility. 18 They were fed standard chow and the antibiotics Borgal (Intervet, Stockholm, Sweden) in the drinking water (1 mL in 310 mL water 2 times per week). All experiments were approved by the local ethics committee. At 7 weeks of age, the mice were randomly grouped (nϭ5 to 8) and injected intraperitoneally with either recombinant mouse IL-18 (50 ng/g body weight) 11 diluted in PBS-BSA, or with PBS-BSA only as a control. The mice received 3 injections per week for 7 weeks, were euthanized at 14 weeks of age, and analyzed for atherosclerotic lesion development. To evaluate the role of exogenous IL-18 on the expression of IFN-␥ and CXCL16 in lesions and spleens, and to avoid possible side effects caused by long-term cytokine treatment, an additional experiment with shortterm injection of IL-18 was applied. Randomly selected groups of female SCID/apoE KO mice (nϭ9 to 10) were injected intraperitoneally with either recombinant mouse IL-18 (100 ng/g body weight) diluted in PBS-BSA or PBS-BSA only, and received a second injection after 24 hours. The mice were euthanized 4 hours after the last injection for intracellular fluorescence-activated cell sorter (FACS) staining (nϭ4) or after 6 hours for mRNA preparation (lesion nϭ5 to 6, spleen nϭ6 to 8, aorta nϭ9 to 10).
Lesion Quantification, Serum CH, TG, SAA, and IFN-␥ Assays
Because of the fact that there is no lesion detectable outside of the aortic root of SCID/apoE KO mice at this age (Zhou et al unpublished findings), the root of aorta was chosen for lesion development assay. Blinded analysis of lesion size in the aortic root was made according to a previously described protocol. 29 To determine the levels of total cholesterol, high-density lipoprotein cholesterol, triglyceride, serum amyloid A protein (SAA), and IFN-␥ in the circulation, blood was collected by heart puncture in conjunction with termination. Total serum cholesterol, high-density lipoprotein cholesterol, and serum triglyceride were determined by adding 10 L of serum onto Vitros II slides and measuring with Vitros DT60II Chemistry System (Ortho-Clinical Diagnostics, Rochester, NY). Serum levels of IFN-␥ and SAA were measured with enzyme-linked immunosorbent assay (ELISA) (OptEIA mouse IFN-␥ set, #555138; Pharmingen, Calif; and Mouse SAA immunoassay Kit, #KMA0012; Biosource, Nivelles, Belgium). All procedures were performed according to the manufacturers' instructions. Before diluting the blood for the ELISA assays, the mouse sera were centrifuged at 14 000g for 30 minutes to remove chylomicrons from the sera.
Real-Time Reverse-Transcriptase Polymerase Chain Reaction for Quantification of IFN-␥ and CXCL16 Expression
Total RNA was extracted from the lesions in the root of aorta, from the spleens, and from the healthy abdominal aorta after the shortterm treatment. The spleens were frozen in dry ice directly after the euthanization. To avoid the possible degradation of the sample RNA, the aorta was perfused with RNAlater (#76104; Qiagen, Hilden, Germany) and kept in the same buffer during the isolation of the lesions from the aortic root and the isolation of the healthy abdominal aorta from adventitia. The isolation was performed under a microscope. Total RNA was prepared using an RNeasy Kit (#74104; Qiagen, Hilden, Germany). Good quality of the RNA was confirmed by a 2100 Bioanalyzer (Agilent). The mRNA levels of IFN-␥ and CXCL16 were quantified by real-time reversetranscriptase polymerase chain reaction (RT-PCR) as previously described. 30 The following primers and probes were applied: mouse IFN-␥: FW, 5-AGCAACAGCAAGGCGAAAA-3; RW, 5-CTGGA-C CTGTGGGTTGTTGA-3; and TM, 5-CCTCAAACTTGGCAAT-ACTCATGAATGCATCC-3; mouse CXCL16: FW, 5-TCCTTTTC-TTGTTGGCGCTG-3; RW, 5-CAGCGACACTGCCCTGGT-3; and TM, 5-TGACCCTGCCAGGCGATGGC-3. The real-time RT-PCR data are expressed as relative mRNA units normalized to mouse 18S ribosomal mRNA expression. Mouse 18S was quantified by a predeveloped TaqMan assay (#4310893E; Applied Biosystems, Warrington, UK).
Immunohistochemistry Staining
To characterize the inflammation of the lesions, we performed immunostaining on sections of the aortic root. The protocol has been described in previous publications. 17, 31 Antibodies used are shown in the 
Flow Cytometry
To exclude a potential "leakage," ie, appearance of T and B cells, which has been reported in aged SCID mice, 32 we assessed the frequency of T and B cells by flow cytometry in all experimental mice. Splenocytes were stained on ice for 30 minutes with fluorescein isothiocyanate-conjugated anti-CD3 and PE-anti-CD19 antibodies (Table) , and analyzed with a FACSCalibur flow cytometer (Becton Dickinson, Mountainview, Calif). For intracellular cytokine staining, splenocytes from short-term treated mice were first stained on ice for 20 minutes with PE-anti-CD11b or PE-anti-NK1.1 antibodies (Table) in PBS with 5% FCS and 10 g/mL Brefeldin A, then fixed 20 minutes on ice in 2% formaldehyde, permeabilized 10 minutes at RT in PBS with 5% fetal calf serum and 0.5% saponin, stained for 30 minutes at RT with fluorescein isothiocyanate-anti-IFN-␥ antibody (Table) in PBS with 5% fetal calf serum and 0.5% saponin, and finally analyzed with a FACSCalibur.
Statistics
Results are expressed as meanϮSEM. Data were analyzed by the Mann-Whitney significance test. The significance level was set to PϽ0.05. 
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Results
IL-18 Accelerates Atherosclerosis in the Absence of T Cells With Elevation of IFN-␥ in Circulation
IFN-␥ Is Induced With Elevation of CXCL16 in Both Lesions and Spleens
To further investigate if IFN-␥ was induced systemically and to quantify the cytokine production, the mRNA levels of IFN-␥ in both lesions and spleens were determined by real-time RT-PCR. In comparison with PBS treatment, IL-18 administration significantly induced IFN-␥ expression in both lesions and spleens, suggesting that IL-18 acts systemically (ratio IFN-␥:18S was 7.34Ϯ1.67 versus 0.89Ϯ0.23 in lesions 
IFN-␥ Is Produced by Macrophages, NK Cells, and Vascular Cells in the Absence of T Cells
To identify which cell type that, in addition to the T cells, can secrete IFN-␥ in vivo and accelerate the disease under the stimulation of IL-18, we performed FACS analysis on splenocytes and real-time PCR on healthy aorta from short-termtreated mice. The FACS analysis revealed that both macro- (Figure 4A, 4B, and 4C ). The FACS analysis was additionally performed on spleen cells from male SCID/apoE KO mice with similar results (data not shown). We also detected a significant increase in IFN-␥ mRNA expression in the healthy aorta after IL-18 treatment by real-time RT-PCR (ratio IFN-␥:18S was 6008Ϯ3031 in the IL-18 group versus 1635Ϯ930 in the PBS group) (Figure 4D ), indicating that cells in the vascular wall are also producers of IFN-␥.
Discussion
The results of the present study show: (1) IL-18 has been described as an IFN-␥ inducing factor. 23 It is proposed from clinical studies that IL-18 is a strong predictor of cardiovascular death in stable and unstable angina. 33 Recently, Whitman et al have described that exogenous IL-18 enhances atherosclerosis in an IFN-␥-dependent manner in the apoE KO mouse. 11 However, it is still unknown what cell type responds to IL-18 stimulation in vivo. It has long been believed that activated T cells are the major source of IFN-␥ in atherosclerosis. Lack of T cells in SCID/apoE KO mice results in a 74% reduction in lesion size and a 85% decrease in circulating IFN-␥ levels compared with apoE KO mice, 18 confirming the role of adaptive immunity in atherosclerosis. Nevertheless, lesions containing mainly macrophages still develop in untreated SCID/apoE KO mice. 18 It has been reported that cultured macrophages can be induced to produce IFN-␥. 21 Interestingly, Gerdes et al have found that vascular macrophages and SMCs can secrete IFN-␥ in vitro under the stimulation of IL-18, and these cells can also express receptors for IL-18. 19, 24 Our current in vivo study confirms this observation. In addition, NK cells have been shown to respond to IL-18 by IFN-␥ production in vitro. 34 All these cell types therefore may be of importance in response to IL-18 stimulation and responsible for the IFN-␥ secretion in vivo.
The importance of macrophages and NK cells in the progression of atherosclerosis has been emphasized in animal models. In addition to IFN-␥, these cells also produce many other cytokines, including granulocyte-macrophage colonystimulating factor and IL-10, which can prevent the progression of the disease. 35, 36 It has been reported that IL-18 itself can directly inhibit IL-10 production, 37 enhance NK cell activity, 38 and exhibit biological function in an IFN-␥-independent manner. 39 These reports imply that IL-18 may affect atherosclerosis via an IFN-␥-independent pathway, even though no such experiment is performed in this perspective. Nevertheless, our study shows that IL-18 executes a proatherogenic role in vivo, with induction of IFN-␥ in the absence of T cells. The current data demonstrate that macrophages, NK cells, and vascular cells can be the source of IFN-␥ in vivo in response to IL-18, which is sufficient for the disease progression.
CXCL16 is a recently discovered chemokine of the CXC family 7 and has been associated with the guidance of IFN-␥ producing Th1 and Tc1 cells to infectious sites. 7 Interestingly, CXCL16 is identical in DNA sequence to the newly discovered scavenger receptor SR-PSOX. This receptor has been confirmed to be expressed in lipid-laden macrophages and SMCs in human atherosclerotic lesions. 40, 41 Regulation of CXCL16 expression by IFN-␥ has been detected in vitro in human aortic SMCs and monocytes. 8, 40 Genetic disruption of any of scavenger receptor SR-A or CD36 results in a significant decrease in lesion formation, suggesting that these 2 receptors play a crucial role in the development of atherosclerosis. 42, 43 Although IFN-␥ is well-known as a proathero- genic cytokine, it has been reported that IFN-␥ downregulates expression of SR-A and CD36. 44, 45 Its proatherogenic action has therefore remained unclear. This paradox could now be explained by the findings that IFN-␥ upregulates expression of CXCL16 in vivo in lesions and in monocytes and SMCs in vitro. 40, 8 IFN-␥ also enhances the uptake of oxidized low-density lipoprotein in monocytes and SMCs via the CXCL16 receptor. 40, 8 Our present data have shown that an increased IFN-␥ level was paralleled with a significant elevation of CXCL16 mRNA expression in both lesions and spleens after IL-18 administration. This suggests that the proatherogenic role of IL-18 could partly depend on IFN-␥ mediated upregulation of CXCL16. Interestingly, two studies have recently shown that IL-18 can induce CXCL16 in SMCs. 46, 40 However, no experiment shows a direct effect of IL-18 on CXCL16 expression in the absence of IFN-␥ in either SMCs or macrophages.
In summary, our findings extend the principle of IL-18 as a proatherogenic cytokine and suggest that the proatherogenic effect of IL-18 can occur in the absence of T cells. IFN-␥ secreted by macrophages, NK cells, and vascular cells in vivo is sufficient for disease progression and may involve upregulation of scavenger receptor CXCL16.
